{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:55:33Z","timestamp":1770746133692,"version":"3.49.0"},"reference-count":60,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,1,26]],"date-time":"2020-01-26T00:00:00Z","timestamp":1579996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2016\/23\/D\/ST5\/00242"],"award-info":[{"award-number":["2016\/23\/D\/ST5\/00242"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Greater Poland Cancer Centre","award":["5\/2018\/183"],"award-info":[{"award-number":["5\/2018\/183"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Polyether ionophore salinomycin (SAL) and its semi-synthetic derivatives are recognized as very promising anticancer drug candidates due to their activity against various types of cancer cells, including multidrug-resistant populations. Ovarian cancer is the deadliest among gynecologic malignancies, which is connected with the development of chemoresistant forms of the disease in over 70% of patients after initial treatment regimen. Thus, we decided to examine the anticancer properties of SAL and selected SAL derivatives against a series of drug-sensitive (A2780, SK-OV-3) and derived drug-resistant (A2780 CDDP, SK-OV-3 CDDP) ovarian cancer cell lines. Although SAL analogs showed less promising IC50 values than SAL, they were identified as the antitumor agents that significantly overcome the resistance to platinum-based drugs in ovarian cancer, more potent than unmodified SAL and commonly used anticancer drugs\u20145-fluorouracil, gemcitabine, and cisplatin. Moreover, when compared with SAL used alone, our experiments proved for the first time increased selectivity of SAL-based dual therapy with 5-fluorouracil or gemcitabine, especially towards A2780 cell line. Looking closer at the results, SAL acted synergistically with 5-fluorouracil towards the drug-resistant A2780 cell line. Our results suggest that combinations of SAL with other antineoplastics may become a new therapeutic option for patients with ovarian cancer.<\/jats:p>","DOI":"10.3390\/molecules25030537","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T11:41:57Z","timestamp":1580125317000},"page":"537","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Overcoming Resistance to Platinum-Based Drugs in Ovarian Cancer by Salinomycin and Its Derivatives\u2014An In Vitro Study"],"prefix":"10.3390","volume":"25","author":[{"given":"Marcin","family":"Michalak","sequence":"first","affiliation":[{"name":"Department of Radiation Therapy and Gynecologic Oncology, Greater Poland Cancer Centre, Garbary 15, 61\u2013866 Pozna\u0144, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3615-3768","authenticated-orcid":false,"given":"Micha\u0142 Stefan","family":"Lach","sequence":"additional","affiliation":[{"name":"Radiobiology Lab, Greater Poland Cancer Centre, Garbary 15, 61\u2013866 Pozna\u0144, Poland"},{"name":"The Postgraduate School of Molecular Medicine, Medical University of Warsaw, Ksi\u0119cia Trojdena 2a, 02\u2013109 Warsaw, Poland"},{"name":"Department of Electroradiology, Pozna\u0144 University of Medical Sciences, Garbary 15, 61\u2013866 Pozna\u0144, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0877-1726","authenticated-orcid":false,"given":"Micha\u0142","family":"Antoszczak","sequence":"additional","affiliation":[{"name":"Department of Medical Chemistry, Faculty of Chemistry, Adam Mickiewicz University, Uniwersytetu Pozna\u0144skiego 8, 61\u2013614 Pozna\u0144, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4770-215X","authenticated-orcid":false,"given":"Adam","family":"Huczy\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Medical Chemistry, Faculty of Chemistry, Adam Mickiewicz University, Uniwersytetu Pozna\u0144skiego 8, 61\u2013614 Pozna\u0144, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4742-2465","authenticated-orcid":false,"given":"Wiktoria Maria","family":"Suchorska","sequence":"additional","affiliation":[{"name":"Radiobiology Lab, Greater Poland Cancer Centre, Garbary 15, 61\u2013866 Pozna\u0144, Poland"},{"name":"Department of Electroradiology, Pozna\u0144 University of Medical Sciences, Garbary 15, 61\u2013866 Pozna\u0144, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/00003081-200609000-00004","article-title":"Screening for ovarian cancer","volume":"49","author":"Rosenthal","year":"2006","journal-title":"Clin. Obstet. Gynecol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7150\/jca.7810","article-title":"Current Approaches and Challenges in Managing and Monitoring Treatment Response in Ovarian Cancer","volume":"5","author":"Marcus","year":"2014","journal-title":"J. Cancer."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S1470-2045(11)70123-1","article-title":"Evolution of platinum resistance in high-grade serous ovarian cancer","volume":"12","author":"Cooke","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/cncr.22045","article-title":"Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis","volume":"107","author":"Rocconi","year":"2006","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.2217\/fon.15.251","article-title":"Current state of biomarkers in ovarian cancer prognosis","volume":"11","author":"Au","year":"2015","journal-title":"Futur. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","article-title":"The Dualistic Model of Ovarian Carcinogenesis","volume":"186","author":"Kurman","year":"2016","journal-title":"Am. J. Pathol."},{"key":"ref_8","first-page":"916819","article-title":"Ovarian Cancer Stem Cells: A New Target for Cancer","volume":"2013","author":"Zhan","year":"2013","journal-title":"Therapy"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"23720","DOI":"10.18632\/oncotarget.4690","article-title":"Critical role of Wnt\/\u03b2-catenin signaling in driving epithelial ovarian cancer platinum resistance","volume":"6","author":"Nagaraj","year":"2015","journal-title":"Oncotarget"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"E2939","DOI":"10.1073\/pnas.1206400109","article-title":"Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy","volume":"109","author":"McAuliffe","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"814","DOI":"10.7164\/antibiotics.27.814","article-title":"Salinomycin, a new polyether antibiotic","volume":"27","author":"Miyazaki","year":"1974","journal-title":"J. Antibiot. (Tokyo)."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cell.2009.06.034","article-title":"Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening","volume":"138","author":"Gupta","year":"2009","journal-title":"Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"950658","DOI":"10.1155\/2012\/950658","article-title":"Salinomycin as a Drug for Targeting Human Cancer Stem Cells","volume":"2012","author":"Naujokat","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ejmech.2018.12.057","article-title":"A medicinal chemistry perspective on salinomycin as a potent anticancer and anti-CSCs agent","volume":"164","author":"Antoszczak","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ejmech.2019.05.031","article-title":"Salinomycin and its derivatives\u2013A new class of multiple-targeted \u201cmagic bullets\u201d","volume":"176","author":"Antoszczak","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Kaushik, V., Yakisich, J., Kumar, A., Azad, N., and Iyer, A. (2018). Ionophores: Potential Use as Anticancer Drugs and Chemosensitizers. Cancers, 10.","DOI":"10.3390\/cancers10100360"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1016\/j.tet.2018.07.028","article-title":"Chemical biology of salinomycin","volume":"74","author":"Versini","year":"2018","journal-title":"Tetrahedron"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.bmcl.2014.02.042","article-title":"Synthesis, antiproliferative and antibacterial activity of new amides of salinomycin","volume":"24","author":"Antoszczak","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ejmech.2014.02.031","article-title":"Synthesis, cytotoxicity and antibacterial activity of new esters of polyether antibiotic \u2013 salinomycin","volume":"76","author":"Antoszczak","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.biopha.2018.01.081","article-title":"Salinomycin derivatives exhibit activity against primary acute lymphoblastic leukemia (ALL) cells in vitro","volume":"99","author":"Urbaniak","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejmech.2014.11.037","article-title":"Synthesis, antiproliferative and antibacterial evaluation of C-ring modified colchicine analogues","volume":"90","author":"Rutkowski","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7146","DOI":"10.1016\/j.bmcl.2012.09.068","article-title":"Antiproliferative activity of salinomycin and its derivatives","volume":"22","author":"Janczak","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.bbamem.2015.01.005","article-title":"Electrogenic and nonelectrogenic ion fluxes across lipid and mitochondrial membranes mediated by monensin and monensin ethyl ester","volume":"1848","author":"Antonenko","year":"2015","journal-title":"Biochim. Biophys. Acta - Biomembr."},{"key":"ref_24","first-page":"4542","article-title":"Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression","volume":"49","author":"Harker","year":"1989","journal-title":"Cancer Res."},{"key":"ref_25","first-page":"2993","article-title":"Selective cytotoxic activities of two novel synthetic drugs on human breast carcinoma MCF-7 cells","volume":"29","author":"Badisa","year":"2009","journal-title":"Anticancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1158\/1078-0432.CCR-08-1558","article-title":"Enhancement of Docetaxel Anticancer Activity by a Novel Diindolylmethane Compound in Human Non-Small Cell Lung Cancer","volume":"15","author":"Ichite","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"101042831769503","DOI":"10.1177\/1010428317695035","article-title":"Salinomycin: A new paradigm in cancer therapy","volume":"39","author":"Dewangan","year":"2017","journal-title":"Tumor Biol."},{"key":"ref_29","first-page":"177","article-title":"Chemistry and biology of salinomycin and its analogues. salinomycin and its analogues","volume":"19","author":"Attanasi","year":"2015","journal-title":"Targets In Heterocyclic Systems"},{"key":"ref_30","first-page":"9","article-title":"Synthesis of salinomycin","volume":"1","author":"Brown","year":"1998","journal-title":"J. Chem. Soc. Perkin Trans."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drup.2017.10.003","article-title":"Not only P-glycoprotein: Amplification of the ABCB1- containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins","volume":"32","author":"Genovese","year":"2017","journal-title":"Drug Resist. Updat."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.4155\/fmc-2017-0308","article-title":"Ovarian cancer cells cisplatin sensitization agents selected by mass cytometry target ABCC2 inhibition","volume":"10","author":"Comsa","year":"2018","journal-title":"Future Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S1734-1140(12)70954-4","article-title":"Study of ABCB1 polymorphism frequency in breast cancer patients from Poland","volume":"64","author":"Barczak","year":"2012","journal-title":"Pharmacol. Reports"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1158\/1535-7163.833.3.7","article-title":"Inhibition of ABCB1 (MDR1 ) and ABCB4 ( MDR3 ) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells","volume":"3","author":"Duan","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000086183","article-title":"Mechanisms of drug resistance in cancer chemotherapy","volume":"14","author":"Luqmani","year":"2005","journal-title":"Med. Princ. Pract."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"241763","DOI":"10.1155\/2013\/241763","article-title":"MDR Gene Expression Analysis of Six Drug-Resistant Ovarian Cancer Cell Lines","volume":"2013","author":"Januchowski","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Eckford, P.D., and Sharom, F.J. (2009). ABC Efflux Pump-Based Resistance to Chemotherapy Drugs. Chem. Rev., 2989\u20133011.","DOI":"10.1021\/cr9000226"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.5966\/sctm.2015-0054","article-title":"Drug Transporter-Mediated Protection of Cancer Stem Cells From Ionophore Antibiotics","volume":"4","author":"Boesch","year":"2015","journal-title":"Stem Cells Transl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bcmd.2010.03.008","article-title":"The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor","volume":"45","author":"Riccioni","year":"2010","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ejmech.2018.07.021","article-title":"Biological activity of doubly modified salinomycin analogs \u2013 Evaluation in vitro and ex vivo","volume":"156","author":"Antoszczak","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2147\/OTT.S126463","article-title":"Salinomycin repressed the epithelial-mesenchymal transition of epithelial ovarian cancer cells via downregulating Wnt\/\u03b2-catenin pathway","volume":"10","author":"Li","year":"2017","journal-title":"Onco. Targets. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"261","DOI":"10.5468\/ogs.2016.59.4.261","article-title":"The effect of salinomycin on ovarian cancer stem-like cells","volume":"59","author":"Chung","year":"2016","journal-title":"Obstet. Gynecol. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.3802\/jgo.2017.28.e14","article-title":"Salinomycin reduces stemness and induces apoptosis on human ovarian cancer stem cell","volume":"28","author":"Lee","year":"2017","journal-title":"J. Gynecol. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.canep.2013.02.008","article-title":"Salinomycin inhibits Akt\/NF-\u03baB and induces apoptosis in cisplatin resistant ovarian cancer cells","volume":"37","author":"Parajuli","year":"2013","journal-title":"Cancer Epidemiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1006\/gyno.1996.0134","article-title":"Treatment of Refractory Ovarian Cancer with 5-Fluorouracil and Leucovorin","volume":"61","author":"Donovan","year":"1996","journal-title":"Gynecol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/00000421-199412000-00007","article-title":"Ineffectiveness of continuous 5-fluorouracil as salvage therapy for ovarian cancer","volume":"17","author":"Burnett","year":"1994","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1006\/gyno.1995.1025","article-title":"Intraperitoneal Administration of Cisplatin and 5-Fluorouracil in Residual Ovarian Cancer: A Phase II Gynecologic Oncology Group Trial","volume":"56","author":"Braly","year":"1995","journal-title":"Gynecol. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Wang, F., Dai, W., Wang, Y., Shen, M., Chen, K., Cheng, P., Zhang, Y., Wang, C., Li, J., and Zheng, Y. (2014). The synergistic in vitro and in vivo antitumor effect of combination therapy with salinomycin and 5-fluorouracil against hepatocellular carcinoma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0097414"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Klose, J., Eissele, J., Volz, C., Schmitt, S., Ritter, A., Ying, S., Schmidt, T., Heger, U., Schneider, M., and Ulrich, A. (2016). Salinomycin inhibits metastatic colorectal cancer growth and interferes with Wnt\/\u03b2-catenin signaling in CD133+ human colorectal cancer cells. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2879-8"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ygyno.2019.09.026","article-title":"Gemcitabine for recurrent ovarian cancer\u2014A systematic review and meta-analysis","volume":"155","author":"Berg","year":"2019","journal-title":"Gynecol Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.canlet.2011.05.030","article-title":"Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells","volume":"313","author":"Zhang","year":"2011","journal-title":"Cancer Lett."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1593\/neo.10576","article-title":"Interdependence of gemcitabine treatment, ransporter expression, and resistance in human pancreatic carcinoma cells","volume":"12","author":"Hagmann","year":"2010","journal-title":"Neoplasia."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3389\/fphar.2018.00606","article-title":"Emerging Roles of Nucleoside Transporters","volume":"9","year":"2018","journal-title":"Front Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/jnci\/91.21.1876","article-title":"Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters","volume":"91","author":"Mackey","year":"1999","journal-title":"J Natl Cancer Inst."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.canlet.2015.01.017","article-title":"Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: Overcoming transport defects using a nanoparticle approach","volume":"359","author":"Hung","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_56","first-page":"1457","article-title":"Salinomycin induces apoptosis via death receptor-5 up-regulation in cisplatin-resistant ovarian cancer cells","volume":"33","author":"Parajuli","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1007\/s13277-015-4212-6","article-title":"Apoptotic effects of salinomycin on human ovarian cancer cell line (OVCAR-3)","volume":"37","author":"Kaplan","year":"2016","journal-title":"Tumour Biol."},{"key":"ref_58","first-page":"2705","article-title":"Effect of cellular mass on chondrogenic differentiation during embryoid body formation","volume":"18","author":"Lach","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Blaszczak, W., Lach, M., Barczak, W., and Suchorska, W. (2018). Fucoidan Exerts Anticancer Effects Against Head and Neck Squamous Cell Carcinoma In Vitro. Molecules, 23.","DOI":"10.3390\/molecules23123302"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/3\/537\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:30:30Z","timestamp":1760362230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/3\/537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,26]]},"references-count":60,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["molecules25030537"],"URL":"https:\/\/doi.org\/10.3390\/molecules25030537","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,26]]}}}